Sugi Predict

Sugi Predict / Compounds / SCHEMBL2842972

SCHEMBL2842972

SCHEMBL2842972

COC(=O)/C=C/c1cccc(N)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM4 Q14833 1/20 0.47
▸ CA12 O43570 1/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ TYR P14679 1/20 0.44
▸ CA7 P43166 1/20 0.44
▸ CA9 Q16790 1/20 0.44
▸ CA14 Q9ULX7 1/20 0.44
▸ KDM4E B2RXH2 5/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ TTR P02766 1/20 0.41
▸ APP P05067 1/20 0.41
▸ MAPT P10636 4/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ TP53 P04637 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29404574 1.00 GRM4 (0.47) GRM4CA12CA1CA2TYR
SCHEMBL2842974 1.00 GRM4 (0.47) GRM4CA12CA1CA2TYR
SCHEMBL17321806 0.82 CA12 (0.45) CA12CA1CA2TYRCA7
SCHEMBL3929433 0.81 TGFBR1 (0.45) CA12CA1CA2TYRCA7
SCHEMBL3929435 0.81 TGFBR1 (0.45) CA12CA1CA2TYRCA7
SCHEMBL22165730 0.80 GRM4 (0.58) GRM4CA12CA1CA2TYR
SCHEMBL28884227 0.80 GRM4 (0.58) GRM4CA12CA1CA2TYR
SCHEMBL946118 0.78 KDM4E (0.45) CA12CA1CA2TYRCA7
SCHEMBL412883 0.78 KDM4E (0.45) CA12CA1CA2TYRCA7
SCHEMBL10648968 0.75 KDM4E (0.42) CA12CA1CA2TYRCA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187728-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2025-01-07 — — US disclosed
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-11530180-B2 Alpha-5 beta-1 inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-12-20 — — US disclosed
US-11530180-B2 Alpha-5 beta-1 inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-12-20 — — US disclosed
US-20220220096-A1 JAK1 SELECTIVE KINASE INHIBITOR DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2022-07-14 — — US disclosed
US-11370792-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2022-06-28 — — US disclosed
US-11370792-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2022-06-28 — — US disclosed
US-20220054465-A1 (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER NEXYS THERAPEUTICS, INC. (US) 2022-02-24 — — US disclosed
CN-113348167-A (pyridin-2-yl) amine derivatives as TGF-beta R1(ALK5) inhibitors for the treatment of cancer 奈可萨斯医药有限公司 2021-09-03 — — CN disclosed
WO-2017106352-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2017-06-22 — — WO disclosed
US-8080567-B2 EP2 receptor agonists ASTERAND UK LIMITED (GB) 2011-12-20 — — US disclosed
US-8080567-B2 EP2 receptor agonists ASTERAND UK LIMITED (GB) 2011-12-20 — — US disclosed
US-8080567-B2 EP2 receptor agonists ASTERAND UK LIMITED (GB) 2011-12-20 — — US disclosed
US-20100130556-A1 EP2 RECEPTOR AGONISTS ASTERAND UK LIMITED (GB) 2010-05-27 — — US disclosed
US-20100130556-A1 EP2 RECEPTOR AGONISTS ASTERAND UK LIMITED (GB) 2010-05-27 — — US disclosed
US-20100130556-A1 EP2 RECEPTOR AGONISTS ASTERAND UK LIMITED (GB) 2010-05-27 — — US disclosed
EP-1951701-A2 EP2 RECEPTOR AGONISTS ASTERAND UK LIMITED (GB) 2008-08-06 — — EP disclosed
WO-2007017687-A2 EP2 RECEPTOR AGONISTS ASTERAND UK LIMITED (GB) 2007-02-15 — — WO disclosed
WO-2007017687-A2 EP2 RECEPTOR AGONISTS ASTERAND UK LIMITED (GB) 2007-02-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220220096-A1 JAK1 SELECTIVE KINASE INHIBITOR JAK1, JAK2, JAK3 GRM4 3917/4885CA12 4751/4885CA1 4645/4885
US-12187728-B2 Caffeine inhibitors of MTHFD2 and uses thereof MTHFD2, MTHFD1, NUDT15 GRM4 3359/4885CA12 3736/4885CA1 3764/4885
US-11370792-B2 Caffeine inhibitors of MTHFD2 and uses thereof MTHFD2, MTHFD1, NUDT15 GRM4 3359/4885CA12 3736/4885CA1 3764/4885
US-20100130556-A1 EP2 RECEPTOR AGONISTS PTGER3, PTGER2, CNR2 GRM4 763/4885CA12 1146/4885CA1 1601/4885
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF MTHFD2, MTHFD1, NUDT15 GRM4 3359/4885CA12 3736/4885CA1 3764/4885
US-11530180-B2 Alpha-5 beta-1 inhibitors SCN5A, PSMA5, API5 GRM4 2764/4885CA12 4712/4885CA1 3107/4885
US-20220054465-A1 (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER TGFBR1, TGFBR2, ACVR1 GRM4 3639/4885CA12 3967/4885CA1 4592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.